Trial Profile
Phase 2 Study of CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19) for Adult Patients With Minimal Residual Disease During Upfront Treatment for Acute Lymphoblastic Leukemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Tisagenlecleucel (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 11 Feb 2019 Status changed from active, no longer recruiting to discontinued.
- 10 Dec 2018 Planned End Date changed from 1 May 2019 to 1 Dec 2019.
- 10 Dec 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Jun 2019.